ArticleBMJ open2026
One-stage versus two-stage video-assisted thoracic surgery for synchronous bilateral pulmonary nodules: protocol for a prospective, multicentre, randomised controlled clinical trial in China (OTVATS-2).
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith the increasing detection of synchronous bilateral pulmonary nodules in clinical practice, both one-stage and two-stage video-assisted thoracic surgery (VATS) have been widely applied. This study protocol describes the OTVATS-2 trial, which aims to compare perioperative complications and long-term outcomes between these two surgical strategies. METHODS AND ANALYSIS: A prospective, multicentre, randomised controlled clinical trial will be conducted to compare the surgical outcomes of one-stage versus two-stage VATS in patients with synchronous bilateral pulmonary nodules. A total of 256 patients will be enrolled from three academic institutions in China. This trial is expected to last for 2 years, with patient recruitment starting in July 2025. The primary outcome is perioperative complication rate within 30 days. Secondary outcomes including 5-year overall survival, 5-year disease-free survival, surgical time, blood loss, duration of chest tube, length of stay, postoperative pain scores, quality of life scores as well as anxiety and depression scores. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2025-KY-150) and the institutional review boards of all participating centres, including the Ethics Committees of Peking University Third Hospital and Beijing Hospital. Written informed consent will be obtained from all enrolled participants. Results of the research will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ChiCTR 2500106215.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.